查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球覆膜支架市场 -2023-2030
市场调查报告书
商品编码
1374810

全球覆膜支架市场 -2023-2030

Global Covered Stents Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

覆膜支架是一种带有织物涂层的血管支架，可形成封闭管，但可以像裸金属支架一样扩张。覆膜支架用于血管内外科手术，例如血管内动脉瘤修復术。覆盖支架由覆盖金属支架的织物或移植材料（例如聚四氟乙烯（PTFE））组成。它们在周边动脉疾病管理中具有多种临床应用。

应用包括治疗动脉粥状硬化疾病、封闭医源性血管穿孔或破裂、排除动脉瘤和假性动脉瘤、治疗动静脉瘻管、治疗失败的透析移植物。覆膜支架在先天性心臟介入治疗期间使用，以治疗狭窄或受伤的血管或排除不必要的血管连接。

覆盖支架也用于治疗天然冠状动脉中充满血栓的病变。覆膜支架为血管穿孔提供了有效的救助策略，是排除冠状动脉瘤的手术的替代方案，并且在治疗易碎易发生栓塞的斑块方面具有潜在作用。

市场动态：驱动因素与限制因素

冠状动脉疾病盛行率上升

覆膜支架主要用于治疗可能危及生命的冠状动脉穿孔和冠状动脉瘤。先前的研究表明，使用覆膜支架可提高无事件生存率，无需紧急手术即可处理危及生命的情况，并显着降低死亡率、心臟压塞和主要不良心臟事件的发生率

冠状动脉疾病是由向心臟供血的动脉（称为冠状动脉）壁上斑块积聚引起的。斑块由胆固醇沉淀物组成。随着时间的推移，斑块的堆积会导致动脉内部变窄。这个过程称为动脉粥状硬化

例如，根据美国疾病管制与预防中心2023 年更新情况说明书，冠状动脉心臟病是最常见的心臟病类型，2021 年将导致375,476 人死亡。20 岁及以上的成年人中约有二分之一患有CAD （约5%） .2 到 2021 年，大约十分之二的 CAD 死亡病例发生在 65 岁以下的成年人中。

此外，覆膜支架技术的进步、老年人口盛行率的上升、冠状动脉疾病盛行率的增加以及支架置入术患者预后的改善。药物洗脱支架 (DES) 技术的进步包括不断完善现有平台，以改善支架输送并开发更俱生物相容性的药物聚合物。

市场动态：克制

覆膜支架最常见的失效机制是输送失败、支架移位和未能密封穿孔。 Graftmaster 的输送失败较常见，而 PK Papyrus 的支架移位较常见。需要进一步改善覆膜支架的设计，以优化输送能力并最大限度地降低併发症的风险。

此外，这些专用医疗设备的成本很高。覆膜支架通常比传统支架更昂贵，这可能会限制其采用，特别是在医疗保健预算有限的地区。此外，熟练部署覆膜支架的熟练介入性心臟病专家的数量有限，进一步阻碍了整个市场的发展。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按产品类型分類的片段
  • 按材料类型分類的片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 冠状动脉疾病盛行率上升
      • 科技进步的崛起
    • 限制
      • 类毒素疫苗的副作用
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 俄乌战争影响分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按产品类型

  • 球囊扩张覆膜支架
  • 裸金属覆盖支架
  • 药物洗脱覆膜支架
  • 生物可吸收覆膜支架

第 8 章：依材料类型

  • ePTFE（膨体聚四氟乙烯）覆盖支架
  • 聚氨酯
  • 聚酯覆盖支架

第 9 章：按应用

  • 週边血管动脉瘤
  • 主动脉缩窄
  • 动脉粥状硬化疾病
  • 冠状动脉穿孔

第 10 章：最终用户

  • 医院
  • 门诊手术中心 (ASC)

第 11 章：心臟专科诊所

第 12 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第13章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 14 章：公司简介

  • Becton, Dickinson and Company
    • 公司简介
    • 产品类型组合和描述
    • 财务概览
    • 主要进展
  • B. Braun Interventional Systems Inc
  • Getinge
  • Insrtumed Surgical, Inc
  • Boston Scientific Corporation
  • Biotronik
  • Mermaid Medical
  • Gore Medical
  • Getz Healthcare
  • avascular SLU

第 15 章：附录

简介目录
Product Code: MD7237

Overview

Covered stent is a type of vascular stent with a fabric coating that creates a contained tube but is expandable like a bare metal stent. Covered stents are used in endovascular surgical procedures such as endovascular aneurysm repair. Covered stents are composed of fabric or graft material, such as polytetrafluoroethylene (PTFE), covering a metal stent. They have various clinical applications in peripheral arterial disease management.

Applications include treatment of atherosclerotic disease, sealing iatrogenic vessel perforations or ruptures, exclusion of aneurysms and pseudoaneurysms, treatment of arteriovenous fistulae, and management of failing dialysis grafts. Covered stents are used during congenital cardiac interventions to treat stenotic or injured vessels or to exclude unwanted vascular connections.

Covered stents were also utilised in thrombus-laden lesions in native coronary arteries. Covered stents offer an effective bail-out strategy in vessel perforations, are an alternative to surgery for the exclusion of coronary aneurysms, and have a potential role in the treatment of friable embolisation-prone plaques.

Market Dynamics: Drivers and Restraints

Rise in the prevalence of coronary artery diseases

Covered stents have been mainly used for the treatment of potentially life-threatening coronary artery perforation and coronary artery aneurysms. Prior studies suggest that the use of covered stents improves event-free survival, enabling a life-threatening situation to be managed without emergency surgery and with significantly reduced rates of mortality, cardiac tamponade, and major adverse cardiac events

Coronary artery disease is caused by plaque buildup in the wall of the arteries that supply blood to the heart (called coronary arteries). Plaque is made up of cholesterol deposits. Plaque buildup causes the inside of the arteries to narrow over time. This process is called atherosclerosis

For instance, according to the Centers for Disease Control and Prevention updated factsheet 2023, coronary heart disease is the most common type of heart disease, killing 375,476 people in 2021. About 1 in 20 adults age 20 and older have CAD (about 5%).2 In 2021, about 2 in 10 deaths from CAD happen in adults less than 65 years old.

Furthermore, technological advancements in covered stents, the rise in the prevalence of the geriatric population, the increase in the prevalence of coronary artery diseases and improvement in patient outcomes with stenting. Advancements in drug-eluting stent (DES) technologies have consisted of continually refining existing platforms to improve stent delivery and develop more biocompatible drug polymers.

Market Dynamics: Restraint

The most common failure mechanisms of covered stents are failure of delivery, stent dislodgement, and failure to seal the perforation. Failure of delivery was more common with Graftmaster, while stent dislodgement was more common with PK Papyrus. Further improvements in covered stent design are needed to optimize deliverability and minimize the risk of complications.

Also, the high cost associated with these specialized medical devices. Covered stents are often more expensive than traditional stents, which can limit their adoption, particularly in regions with constrained healthcare budgets. Moreover, the limited availability of skilled interventional cardiologists proficient in deploying covered stents further hampers the overall market.

Segment Analysis

The global covered stents is segmented based on product type, material type, application, end-user and region.

The balloon expandable vascular-covered stent segment accounted for approximately 41.2% of the market share

The balloon expandable vascular covered stent from the product type segment accounted for 41.2% and it is expected to be dominated during the forecast period. Balloon Expandable Vascular Covered Stent is indicated for the treatment of atherosclerotic lesions in common and external iliac arteries. Balloon-expandable covered stents are medical devices used in interventional cardiology and vascular surgery to treat vascular conditions like aneurysms and stenoses. They consist of a metal framework covered with a synthetic fabric or polymer material.

Moreover, in September 2022, Medtronic set forth that it recently received a CE mark for its Radiant balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the Endurant II/Iis stent graft system. The Endurant II/Iis stent graft and Radiant covered stent offer a standardized, fully on-label, off-the-shelf solution for short-neck, juxtarenal abdominal aortic aneurysms (AAA). This enables safe and effective endovascular repair in both urgent and elective juxtarenal AAA cases, with a proven device combination, backed by clinical outcomes.

Geographical Analysis

Europe accounted for approximately 28.4% of the market share in 2022

Europe is estimated to hold about 28.4% of the total market share throughout the forecast period, owing to the novel product launches, technological advancements, collaboration with the key players, approvals and others that will drive this region further during the forecast period.

For instance, in September 2022, Getinge joined forces with Medtronic to launch a Radiant stent for ChEVAR procedures in Europe which received a CE mark.

Radiant, is the first covered stent which is designed for use in chimney endovascular aneurysm repair (ChEVAR) with the Endurant II/Iis stent graft system. It maintains perfusion to renal arteries when used in combination with the stent graft

Furthermore, in May 2021, iVascular has recently received CE mark approval for its BX-covered stent iCover. Balloon-expanding (BX) covered stents are commonly used for treating arteriosclerotic lesions in renal and iliac arteries and for the treatment of aneurysms and ruptures.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global covered stents market importantly, new studies and registers shows that the percentage of stent thrombosis increased during the COVID-19 pandemic, even up to 8.1-21%, however, the study populations were relatively low. COVID-19, due to direct and indirect effects, creates a significant burden on the cardiovascular system.

Due to the high infection rate and lockdown regulations brought on by the COVID-19 pandemic, surgical procedures have been affected. Additionally, patients with cardiovascular diseases have experienced delays in diagnosis and treatment as a result of fewer people visiting hospitals and diagnostic facilities, which has affected the covered stent market.

Competitive Landscape

The major global players in the covered stents market include: Becton, Dickinson and Company, B. Braun Interventional Systems Inc., Getinge, Insrtumed Surgical, Inc., Boston Scientific Corporation, Biotronik, Mermaid Medical, Gore Medical, Getz Healthcare, iVascular S.L.U and among others.

Why Purchase the Report?

  • To visualize the global covered stents market segmentation-based product type, material type, application, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of covered stents market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global covered stents market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Material Type
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Rise in the prevalence of coronary artery diseases
      • 4.1.1.2. Rise in the technology advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects of Toxoid Vaccine
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Balloon Expandable Covered Stents *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bare Metal Covered Stents
  • 7.4. Drug-Eluting Covered Stents
  • 7.5. Bioabsorbable Covered Stents

8. By Material Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 8.1.2. Market Attractiveness Index, By Material Type
  • 8.2. ePTFE (Expanded Polytetrafluoroethylene) Covered Stents*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Polyurethane
  • 8.4. Polyester Covered Stents

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Peripheral Vascular Aneurysms *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Coarctation of the Aorta
  • 9.4. Atherosclerotic Diseases
  • 9.5. Coronary Artery Perforations

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Ambulatory Surgical Centers (ASCs)

11. Cardiac Specialty Clinics

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.7.1. U.S.
      • 12.2.7.2. Canada
      • 12.2.7.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.7.1. Germany
      • 12.3.7.2. UK
      • 12.3.7.3. France
      • 12.3.7.4. Italy
      • 12.3.7.5. Spain
      • 12.3.7.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. Becton, Dickinson and Company
    • 14.1.1. Company Overview
    • 14.1.2. Product Type Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. B. Braun Interventional Systems Inc
  • 14.3. Getinge
  • 14.4. Insrtumed Surgical, Inc
  • 14.5. Boston Scientific Corporation
  • 14.6. Biotronik
  • 14.7. Mermaid Medical
  • 14.8. Gore Medical
  • 14.9. Getz Healthcare
  • 14.10. avascular S.L.U

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us